**The Trump administration's December 2025 executive order directed expedited rescheduling of marijuana to Schedule III under the Controlled Substances Act.** In April 2026, the Acting Attorney General issued an order immediately moving FDA-approved marijuana products and state-licensed medical marijuana to Schedule III while launching an expedited administrative hearing on broader rescheduling, which ran from June 29 to July 15, 2026. Post-hearing briefs are now under review, with an administrative law judge recommendation expected in late 2026 and a potential final DEA rule to follow. Trader consensus on timing reflects the compressed schedule set by the administration, ongoing procedural steps, and potential for further delays from legal challenges or agency review. Resolution hinges on publication of a final rule in the Federal Register covering all marijuana.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$798,048 Vol.
September 30
16%
December 31
18%
$798,048 Vol.
September 30
16%
December 31
18%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...**The Trump administration's December 2025 executive order directed expedited rescheduling of marijuana to Schedule III under the Controlled Substances Act.** In April 2026, the Acting Attorney General issued an order immediately moving FDA-approved marijuana products and state-licensed medical marijuana to Schedule III while launching an expedited administrative hearing on broader rescheduling, which ran from June 29 to July 15, 2026. Post-hearing briefs are now under review, with an administrative law judge recommendation expected in late 2026 and a potential final DEA rule to follow. Trader consensus on timing reflects the compressed schedule set by the administration, ongoing procedural steps, and potential for further delays from legal challenges or agency review. Resolution hinges on publication of a final rule in the Federal Register covering all marijuana.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions